Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports
ABSTRACT The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Digital revista |
| Language: | English |
| Published: |
Conselho Brasileiro de Oftalmologia
2022
|
| Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27492022000400411 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|